Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study Meeting Abstract
| Authors: | Eyre, T.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Maranda, E.; Woyach, J.; Wierda, W. G.; Cheah, C. Y.; Roeker, L.; Patel, M. R.; Fakhri, B.; Barve, M. A.; Tam, C. S.; Lewis, D.; Gerson, J. N.; Alencar, A.; Taylor, J.; Abedel-Wahab, O.; Ghia, P.; Schuster, S. J.; Chen, J.; Nair, B.; Tsai, D. E.; Ku, N. C.; Davids, M. S.; Brown, J. R.; Jurczak, W.; Mato, A. R. |
| Abstract Title: | Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study |
| Meeting Title: | 61st Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 193 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Apr 25-28 |
| Meeting Location: | Virtual |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2021-04-01 |
| Start Page: | 37 |
| End Page: | 38 |
| Language: | English |
| ACCESSION: | WOS:000645412200039 |
| PROVIDER: | wos |
| PUBMED: | 33928641 |
| DOI: | 10.1111/bjh.17490 |
| Notes: | Meeting Abstract: BSH2021-OR-038 -- Omar Abdel-Wahab's name is misspelled on the original publication -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
573Abdel-Wahab -
235Mato -
132Roeker
Related MSK Work